1. World Health Organization: Bronchial Asthma; Web link:
http://www.who.int/mediacentre/factsheets/fs307/en/
. Accessed 2 Oct 2015.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; Web Link:
http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
. (Accessed 22 Mar 2017).
3. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–207.
4. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–9.
5. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;4:CD007313.